Search

Home > GRACEcast Lung Cancer Video > ASCO Lung Cancer Highlights, Part 6: Predicting Benefit of Chemotherapy vs. EGFR Inhibitor Therapy in Second Line (video)
Podcast: GRACEcast Lung Cancer Video
Episode:

ASCO Lung Cancer Highlights, Part 6: Predicting Benefit of Chemotherapy vs. EGFR Inhibitor Therapy in Second Line (video)
Category: Science & Medicine
Duration: 00:06:38
Publish Date: 2013-08-16 21:19:15
Description:

Dr. David Gerber, University of Texas-Southwestern, reviews the results of the PROSE study of the Veristrat serum proteomics test to predict benefit of chemo or EGFR inhibitor for second line treatment of advanced lung cancer.
Total Play: 0